thanks for joining us today.
compname reports q1 results; q4 sales increase of 16%.
non-gaap quarterly results.
ex continues to make great progress in q3 with revenue up 16%.
compname announces agreement to receive payment for asbestos settlement with group.
q3 earnings per share $0.49.
compname says inpivoted common stock repurchases were completed through settlement provisions of co's existing agreements and were executed by q4.
final results of fiscal 2021 completed during third quarter of 2021.
compname announces $87.2 million increase in full year 2022 base rate.
reaffirms fy 2021 guidance.
qtrly total base rate increase $94.6 million, or 3.3%.
qtrly operating margin 10%.
compname says settlement constitutes a number of important financial provisions.
pandit provides consent for revises 5-year capital expenditures guidance and expects cost deferral order plus rate adjustment for co's selective catalytic reduction equipment to be reduced by four to five percent.
previously provided q2 2021 capital expenditures forecast includes a $100 million share repurchase program with cash of about $150 million and $30 million in 2019.
co's board approved $4 billion share repurchase program.
